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Abstract
Background Local treatments to alleviate symptoms in
hand osteoarthritis (OA) are preferred, especially in elderly
patients with comorbidities. Therefore, we have summarized
the benefits and harms of intra-articular (IA) therapies.
Methods We conducted a systematic literature review
until May 2015, including all controlled trials investigating
efficacy or safety of any IA therapy in carpometacarpal
(CMC) and interphalangeal (IP) OA compared with pla-
cebo or other treatments. Two authors independently
selected trials and assessed risk of bias using the Cochrane
tool. The main efficacy outcome was pain. We performed
meta-analysis where appropriate.
Results A total of 13 trials (864 patients) studying CMC
(n = 11) and IP OA (n = 2) were included, comparing
corticosteroids or hyaluronic acid (HA) versus placebo
(n = 4 and n = 3), and corticosteroids versus HA (n = 6).
Single studies investigated infliximab, dextrose, and dif-
ferent HAs. The overall risk of bias was unclear or high in
most trials. Meta-analysis of two trials comparing
corticosteroids with placebo in CMC OA showed no
improvement in pain [mean difference -3.56, 95 % con-
fidence interval (CI) -13.87 to 6.75, scale 0–100). HA also
appeared not efficacious compared with placebo in CMC
OA. One trial comparing corticosteroids with placebo in IP
OA demonstrated significantly improved pain during
movement. No convincing evidence for efficacy of corti-
costeroids or HA over the other or alternative therapies was
found. Only local adverse events were reported. No specific
IA therapy appeared more harmful than another.
Conclusion Despite a beneficial short-term safety profile,
IA corticosteroids or HA do not appear more effective than
placebo in CMC OA. The suggestion that IA corticosteroids
might be efficacious in IP OA requires confirmation.
Key Points
Despite a beneficial short-term safety profile, intra-
articular corticosteroids or hyaluronic acid do not
appear more effective than placebo in thumb-base
osteoarthritis.
Intra-articular corticosteroids might be efficacious in
interphalangeal osteoarthritis, although this finding
requires confirmation.
1 Introduction
Hand osteoarthritis (OA) is a prevalent joint disorder with a
high burden of disease, leading to pain, loss of function and
a decreased quality of life [1–3]. The prevalence of
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symptomatic hand OA among men and women aged
[70 years was estimated to be 13 and 26 %, respectively,
in a large population-based cohort study [3], and the
prevalence of radiographic hand OA is even higher,
affecting up to 55 and 67 % of men and women over the
age of 55 years [1]. No treatments are yet available to
modify the disease course [4]. The main aim for therapies
in hand OA is therefore to alleviate symptoms. For this
purpose, non-pharmacological treatments (e.g. education,
the use of assistive devices, and the application of splints
for thumb base OA) as well as pharmacological treatment
modalities [most importantly simple analgesics like
paracetamol and non-steroidal anti-inflammatory drugs
(NSAIDs)] are available. The European League Against
Rheumatism (EULAR) recommends a combination of non-
pharmacological and pharmacological treatment modalities
for the optimal management of hand OA, with a preference
for local treatments over systemic treatments [5]. Local
treatment could be an attractive treatment modality, espe-
cially in elderly patients with more comorbidities.
A well-known, widely used form of local treatment is the
injection of corticosteroids into the affected joint, particu-
larly for patients with thumb-base OA [6]. The local anti-
inflammatory effects of corticosteroid injections are
hypothesized to decrease inflammation and consequently
relieve the symptoms of OA. However, important side
effects like infectious arthritis and cartilage damage have
been described, although these adverse events are infrequent
[7]. The EULAR 2007 recommendations advocate the use of
intra-articular injection of corticosteroids to alleviate painful
flares of OA, especially in thumb-base OA, based on expert
opinion [5]. However, this recommendation was not sup-
ported by the 2012 American College of Rheumatology
(ACR) recommendations for the management of OA, which
‘‘conditionally recommends not using intra-articular corti-
costeroids’’ in thumb-base OA [8].
Another well-known intra-articular treatment is the
injection of hyaluronic acid in the osteoarthritic joint
(commonly called viscosupplementation). Viscosupple-
mentation is based on the physiologic importance of
hyaluronan in the synovial fluid, and it is hypothesized that
this can restore the reduced viscoelasticity of the synovial
fluid in osteoarthritic joints and thus decrease pain,
improve mobility and restore the natural protective func-
tions of hyaluronan in the joint [9, 10]. Reported side
effects include local reactions, but also more serious side
effects like pseudoseptic reactions and flare-ups of the
disease [11, 12]. Experts do not yet agree on the usefulness
of this form of intra-articular therapy, since EULAR
guidelines specify that intra-articular hyaluronan may be
useful in treating thumb-base OA, whereas ACR guidelines
conditionally recommend not using intra-articular hyalur-
onates [5, 8].
A recent systematic review assessing the efficacy of
intra-articular injections of corticosteroids and hyaluronic
acid in thumb-base OA concluded that intra-articular hya-
luronic acid may be useful to increase functional capacity
and that intra-articular corticosteroids can decrease pain in
thumb OA after 24 weeks [13]. However, the authors
found large heterogeneity in the results of their meta-
analysis. Moreover, they did not include other subsets of
OA, e.g. interphalangeal (IP) OA and erosive OA, and
excluded trials that assessed other intra-articular therapies
besides corticosteroids or hyaluronic acid.
The aim of the present study was to assess the benefits
and harms of all forms of intra-articular therapies in the
treatment of hand OA, including all its subsets.
2 Methods
We conducted a systematic literature review, including all
published randomised controlled trials (RCTs) and quasi-
RCTs (i.e. where allocation was not truly random), without
language restrictions. We included trials of adults with
hand OA, regardless of its subset (including thumb-base
OA, IP OA and erosive OA), as determined by clinical
diagnosis or fulfilment of the ACR criteria for hand OA
[14]. Studies including participants with other diseases
were only eligible if the results from participants with hand
OA were presented separately. We included studies that
compared any form of intra-articular therapy in the hand
joints (including, but not restricted to, corticosteroids and
hyaluronic acid) versus placebo; another intra-articular
therapy; another pharmacological therapy; a non-pharma-
cological treatment; or different doses, frequency or dura-
tion of the same therapy. Studies that did not assess any
efficacy or safety outcomes were not eligible for inclusion.
2.1 Search Strategy
We searched the following databases up to May 2015:
PubMed, Embase, the Cochrane Library, the Cochrane
Central Register of Controlled Trials (CENTRAL), Web of
Science, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Academic Search Premier and Sci-
enceDirect. The complete search strategy is provided in the
Electronic Supplementary Material (ESM). Additionally,
we searched three clinical trial registries to identify
ongoing and recently finished studies [ClinicalTrials.gov,
the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal
and the International Standard Randomised Controlled
Trial Number (ISRCTN) registry]. We contacted authors of
completed but still unpublished trials that were identified in
clinical trial registries to request more information about
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their study. We also screened conference abstracts of the
EULAR, ACR and OsteoArthritis Research Society Inter-
national (OARSI) annual conferences from the last 5 years,
as well as reference lists from included studies and other
systematic reviews on the safety and efficacy of intra-ar-
ticular therapies for hand OA. We contacted authors of
eligible studies that were published only as a conference
abstract for additional information, and excluded confer-
ence abstracts published more than 5 years ago.
2.2 Study Selection and Data Collection
Two review authors (FK, RR) independently screened the
retrieved titles and abstracts, and full-text papers were
retrieved and read if necessary to determine inclusion.
Disagreements between the authors were discussed in a
consensus meeting. In case of non-consensus, a third
reviewer (MK) decided whether the study was eligible.
One review author (FK) extracted data from each included
study regarding study design, study duration, characteris-
tics of the study population, interventions, outcome mea-
sures, timing of outcome assessment, co-interventions,
results for outcomes of interest, losses to follow-up and
funding. A second review author (RR) verified extracted
data.
2.3 Assessment of Risk of Bias
Two review authors (FK, RR) independently assessed the
risk of bias of each included study with regard to random
sequence generation, allocation concealment, blinding (of
participants, care provider and outcome assessor), incom-
plete outcome data, selective outcome reporting and other
sources of bias according to the Cochrane risk of bias tool
[15]. Each criterion was judged as ‘low risk of bias’, ‘high
risk of bias’ or ‘unclear’ (either lack of information or
uncertainty over the potential for bias). In addition, an
‘overall assessment’ was formed for each study, based on
the individual judgements for each risk of bias item. Items
assessing selection bias and blinding were considered ‘key
domains’, i.e. the most important domains in the risk of
bias of a study. Studies were judged as having an overall
high risk of bias if one or more items from the ‘key
domains’ were judged as high risk. In cases where both key
domains were judged as unclear risk, that study was rated
as having an overall high risk of bias when more than two
of the three remaining items were both rated high or
unclear, and it was rated as having an overall unclear risk
of bias when two of the remaining items were rated as low
and unclear risk or if at least two items were both rated as
low risk. In cases where both key domains were judged as
low risk, that study was rated as having an overall unclear
risk of bias when more than two remaining items were both
rated high or unclear, and it was rated as having an overall
low risk of bias when two of the remaining items were
rated as low and unclear risk or if at least two items were
rated as low risk. Disagreements were discussed, and in
case of non-consensus a third review author (MK) made
the final decision.
2.4 Outcome Measures
All outcomes were assessed at baseline, week 4, week 12
and week 24. The main efficacy outcome was pain on a
visual analogue scale (VAS) or a numerical rating scale
(NRS). Other efficacy outcomes were self-reported physi-
cal function, patient global assessment, joint activity,
health-related quality of life and hand strength, according
to the core domains in clinical trials for hand OA proposed
by Outcome Measures in Rheumatology (OMERACT)
[16]. The safety outcomes that were assessed included the
number of withdrawals due to adverse events, the number
of (local or systemic) adverse events and the number of
serious adverse events.
2.5 Data Analysis
Meta-analysis was only performed if the study data were
clinically and statistically sufficiently homogeneous and/or
the risk of bias was judged to be low enough to produce
reliable results, using Review Manager 5.3 statistical
software. For studies judged as clinically homogeneous
with respect to intervention groups, control groups, timing
of outcome assessment and outcome measures, the I2
statistic was used to test for statistical heterogeneity. For
continuous outcomes, mean differences (MDs) with cor-
responding 95 % confidence intervals (CIs) were calcu-
lated, unless different scales were used to measure the
same conceptual outcome (e.g. pain), in which case the
standardised mean difference (SMD) was calculated with
corresponding 95 % CIs. SMDs are calculated by dividing
the MD by the standard deviation (SD), resulting in a unit-
less measure of effect. For dichotomous outcomes, the
results were expressed as risk ratios (RRs) with corre-
sponding 95 % CIs. A random-effects model was used as
the default option to be conservative in all analyses,
independent of the I2. The sample mean and SD was esti-
mated from studies reporting only the median and (in-
terquartile) range, using the appropriate approximation
method proposed by Wan et al. [17]. Studies that could not
be included in the meta-analysis were described
narratively.
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3 Results
3.1 Description of Included Studies
Database searching initially identified 2157 records, of
which 24 qualified for full review, and 13 studieswere finally
included (see Fig. 1) [18–31]. We additionally identified 42
studies in clinical trial registries, of which two were eligible
for inclusion. However, both trials were finally excluded as,
upon request for more information from the authors, one trial
appeared to be terminated prematurely due to adverse events
in the intervention group, and the other trial was completed
but results were not published because the pharmaceutical
company did not pursue the indication.No additional records
were found through other sources. All disagreements
between the authors (FK, RR) on article selection (n = 6)
were resolved in a consensus meeting.
A total of 13 studies involving 864 participants (range
20–200, median 60), published between 2004 and 2014
were included. The mean age of participants was
62.8 years (reported in 12 trials). Four studies only inclu-
ded women, and in the other nine studies 84.5 % of the
participants were women. Most studies (n = 11) only
included participants with carpometacarpal (CMC) OA,
and two trials only included participants with IP OA [20,
30], of which one study specifically included participants
with erosive OA [20]. In many studies (n = 11), radio-
graphic evidence of OA had to be present on top of clinical
signs and symptoms.
Four trials compared corticosteroids with placebo; three
trials compared hyaluronic acid with placebo; six studies
compared corticosteroids with hyaluronic acid; and single
studies compared infliximab with placebo, corticosteroids
with dextrose, different frequencies of hyaluronic acid
injections and hyaluronic acid with a low versus a high
molecular weight (Table 1). A total of 280 participants
were treated with intra-articular corticosteroid injections:
three trials used triamcinolone acetonide (dose range
10–40 mg in 0.5–1 ml, injected once in all studies) [18, 21,
24], two studies used triamcinolone hexacetonide (dose
range 4–6 mg in 0.2–0.3 ml, injected once in both studies)
[26, 30], two studies used betamethasone (3 mg in 0.5 ml
injected three times in one trial, and a single injection of an
unknown dose in 1 ml in the other) [22, 27], and two
studies used methylprednisolone (40 mg in 0.5–1 ml
injected once in both studies) [23, 31]. Two trials added a
small dose of lidocaine 2 % to the injection fluid [23, 30].
A total of 360 participants were treated with intra-articular
hyaluronate injections: three studies used Hylan G-F 20
(8 mg in 1 ml, injected once or twice) [19, 22, 24], six
studies used sodium hyaluronate (dose range 5–15 mg in
0.5–1 ml, injected one to three times) [18, 21, 25, 27–29,
31]. A total of 172 participants were treated with placebo,
comprising a saline injection of 0.2–1 ml in four studies
[19, 20, 22, 26] or a local anaesthetic in two studies (0.1 ml
lidocaine 2 % or 0.5 ml bupivacaine 0.5 %) [24, 30].
Finally, 30 participants in one trial were treated with intra-
articular dextrose 20 % injections (0.5 ml, combined with
2157 records idenﬁed through 
database searching 
(Pubmed 430, Embase 1048, Cochrane 38, 
CENTRAL 38, Web of Science 408, CINAHL 
51, Academic Search Premier 94, 
ScienceDirect 50)
1398 records aer duplicates removed 
1364 records excluded 
based on tle and abstract
34 full-texts assessed for eligibility 
18 full-texts excluded 
Reasons: Database search (n=10): 3 no 
comparator, 2 wrong intervenon, 1 wrong 
joint, 4 wrong study design 
Trial databases (n=8): 2 sll recruing, 
2 sll ongoing, 1 trial status unknown, 
1 terminated, and 2 eligible but results not 
published
13 studies included in review
(Roux 2007 was reported in 2 papers, 
2 eligible clinical trial records were 
already included as a full report)
42 records idenﬁed in 
trial databases 
(Clinicaltrials.gov 17, ISRCTN 11, WHO 
ICTRP 14)
1398 records screened
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0.5 ml lidocaine 2 %, injected three times monthly) [23],
and ten participants were treated with intra-articular
infliximab injections (0.2 ml, 0.1 mg/ml, injected 12 times
monthly) [20].
3.2 Risk of Bias
Most trials were assessed as being at high or unclear risk of
bias for multiple items (Fig. 2). In the overall assessment,
only two studies were judged as having a low risk of bias
[26, 30]. Four trials were at low risk of selection bias, as
they described adequate sequence generation and alloca-
tion concealment; the risk of selection bias in the other
trials was high (n = 3) or unclear (n = 6). One additional
trial was at high risk of selection bias even though
sequence generation and allocation concealment were
performed using methods associated with a low risk of
bias, since this study selectively included participants
based on the probability of a positive treatment effect
(judged as high risk of bias in the item ‘other bias’) [22].
Participants were adequately blinded in five trials;
however, in the remaining studies, participants were not
blinded (n = 4) or it was unclear whether participants were
blinded (n = 4), although most trials (n = 8) adequately
blinded the outcome assessor(s). One trial had unexplained
incomplete outcome data and was assessed as being at high
risk of attrition bias. The risk of attrition bias remained
unclear in seven trials, for example because the number of
participants finishing the study was not described (n = 5).
Many trials had a high risk of reporting bias (n = 5), e.g. as
they did not report all assessed outcomes at all time points
or only reported p values. Other potential sources of bias
were identified in five trials and included inappropriate
statistical analyses for the selected study design (n = 2)
[19, 20], exclusion of participants after inclusion [23] or
after treatment allocation [27], and selectively including
patients based on probability of a positive treatment effect
(n = 2) [20, 22].
3.3 Effects of Interventions
Most studies were clinically too heterogeneous to compare,
did not provide data eligible for meta-analysis (e.g. data
only presented in figures, or presentation of point estimates
without a measure of variance), and/or the risk of bias was
judged to be too high to produce reliable results. Only
results of two studies, comparing corticosteroid injections
versus placebo in participants with CMC OA, could be
pooled [24, 26]. The remaining studies are discussed nar-
ratively under each relevant comparison. A summary of the
most important findings is presented in Table 2.
3.3.1 Intra-Articular Corticosteroids Versus Placebo
Three studies (n = 206) compared a corticosteroid injec-
tion with placebo in participants with CMC OA [22, 24,
26]. Pooled results from two studies (n = 166, unclear and
low risk of bias) for our primary outcome measure pain on
VAS showed no difference up to 26 weeks between intra-
articular corticosteroids and placebo [MD -3.56 (95 % CI
-13.87 to 6.75) on a 100-mm VAS; Fig. 3]. The third
study (n = 40, unclear risk of bias) concluded that both
groups showed a decrease in pain compared with baseline,
although there were no significant between-group differ-
ences at any of the time points up to 26 weeks (data only
presented graphically). Also, for the other reported efficacy
outcomes [i.e. function (two trials), grip strength (one
trial), pinch strength (one trial), pain on joint palpation (one
trial), joint stiffness (one trial), patient global assessment
(one trial), physician global assessment (one trial) and
range of motion (one trial)], no between-group differences
up to 26 weeks were found by any study in this compari-
son. No adverse events were observed in any of the treat-




































































             
Figen[19]                
Fioravan[20]                
Fuchs[21]                
Heyworth[22]                
Jahangiri[23]                
Mandl[24]                
Massaro[25]                
Meenagh[26]                
Monfort[27]                
Roux[28, 29]                
Spolidoro[30]                
Stahl[31]                
Fig. 2 Risk of bias summary: review author’s judgement about each
risk of bias item for each included study (? indicates low risk of bias,
- indicates high risk of bias, ? indicates unclear risk of bias,
* indicates overall assessment based on the individual judgements for
each risk of bias item)
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adverse events in both treatment groups [9/65 in the cor-
ticosteroid group (all local adverse events such as pain,
swelling and skin or nail abnormalities) and 3/61 in the
placebo group (of which two were local adverse events and
one was a surgery unrelated to study medication)].
Spolidoro et al. [30] (n = 60, low risk of bias) studied
participants with IP OA and found a decrease in pain
compared with baseline for both groups, although there
were no between-group differences for pain at rest at any of
the time points up to 12 weeks. However, pain during joint
movement improved more in the corticosteroid group than
in those receiving placebo after 12 weeks [mean (SD) score
on a 10-cm VAS after 12 weeks of 2.2 (2.9) vs. 4.0 (3.2),
respectively]. Also, a significant decrease in joint swelling
was found in the corticosteroid-treated group compared
with the placebo group [1.1 (1.2) vs. 2.0 (1.3), respectively
on a 10-cm VAS]. For the other reported efficacy outcomes
(i.e. function [measured with both the Cochin questionnaire
and the Australian/Canadian hand osteoarthritis index
(AUSCAN)], grip strength, pinch strength and goniome-
try), no between-group differences were identified. The
authors reported that no severe adverse events were
observed in either treatment group.
3.3.2 Intra-Articular Hyaluronic Acid Versus Placebo
Three studies (n = 196) investigated an injection with
hyaluronic acid compared with placebo in participants with
CMC OA [19, 22, 24]. One trial investigated the same
participants in both treatment groups by including one
CMC joint in the intervention group and the contralateral
joint in the placebo group [19]. All studies [risk of bias:
high (n = 1) and unclear (n = 2)] showed a decrease in
pain compared with baseline in both groups, but no sig-
nificant between-group differences were found up to
26 weeks in two studies, while one study did not formally
investigate between-group differences. Furthermore, no
between-group differences were reported for the other
efficacy outcomes [i.e. function (three trials), grip strength
(one trial), pinch strength (two trials) and range of motion
of the thumb (one trial)]. No adverse events were observed
in any of the treatment groups in two trials, although one
trial [24] observed adverse events in both treatment groups
[5/62 in the hyaluronic acid-group (three local adverse
events and two cases of surgery unrelated to study medi-
cation) and 3/61 in the placebo group (two local adverse
events and one case of surgery unrelated to study
medication)].
3.3.3 Intra-Articular Corticosteroids Versus Hyaluronic
Acid
Six studies (n = 405) investigated a corticosteroid injec-
tion compared with hyaluronic acid in participants with
CMC OA [18, 21, 22, 24, 27, 31]. For the primary out-
come—pain on VAS—all trials showed an improvement in
both treatment groups. Four trials [risk of bias: high
(n = 2) and unclear (n = 2)] showed no between-group
difference in pain on VAS up to 26 weeks [22, 24, 27, 31],
one trial (high risk of bias) described a transitory superior
effect of corticosteroids at 1 and 6 months [18], and one
trial (high risk of bias) concluded that the corticosteroid
group initially displayed a better and faster pain relief up to
3 weeks but that hyaluronic acid was ‘non-inferior’ to
corticosteroids thereafter [21]. Three studies [risk of bias:
high (n = 1) and unclear (n = 2)] reported no between-
group differences in self-reported function after 26 weeks
[22, 24, 27], although one trial (high risk of bias) reported
temporarily more improvement in function in the corti-
costeroid group at 12 months of follow-up [18]. Three of
four trials assessing self-reported function reported an
improvement in function in both intervention groups [18,
22, 27]. No between-group differences were found for most
other reported efficacy parameters [i.e. grip strength (one
trial), pinch strength (one trial), range of motion of the
thumb (one trial), joint pain on pressure (one trial), quality
Fig. 3 Forest plot: comparison of intra-articular corticosteroids
versus placebo in participants with thumb-base OA, outcome pain
on VAS. The studies included in the forest plot were Mandl et al. [24]
and Meenagh et al. [26]. CI confidence interval, df degrees of
freedom, IV inverse variance, mm millimetres, SD standard deviation,
VAS visual analogue scale
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of life (one trial) and joint crepitation (one trial)]. However,
single studies reported temporarily more improvement in
grip strength in the corticosteroid group at 1 month of
follow-up [18], and transitory better relief of joint swelling
in the corticosteroid group [21]. In contrast, single studies
also reported (transitory) beneficial effects in favour of
hyaluronic acid injections in the outcomes pinch strength
(temporarily more improvement after 12 weeks [22] and
24 weeks [21]), range of motion of the thumb (overall
more improvement in the hyaluronic acid group [21]) and
joint warmth (overall better relief of warmth in the hya-
luronic acid group [21]). One trial only reported effects
within each treatment group without formally comparing
the two interventions for the outcomes function perfor-
mance, grip strength and pinch strength [31].
Three trials reported adverse events in both treatment
groups, although numbers were relatively low and equal in
both groups [corticosteroid vs. hyaluronic acid groups:
4/28 vs. 4/28 (Fuchs et al. [21], not related to study med-
ication), 5/40 vs. 5/48 (Monfort et al. [27], minor side
effects, including pain and local swelling following the
injection), 9/65 vs. 5/62 (Mandl et al. [24], local side
effects such as pain, swelling and skin and nail abnor-
malities, and few cases of surgery unrelated to study
medication)], although no adverse events were observed in
any of the treatment groups in the remaining three studies
in this comparison.
3.3.4 Other Comparisons
One study (n = 20, high risk of bias) investigated intra-
articular infliximab injections compared with placebo in a
non-randomised pilot study in participants with erosive IP
OA [20]. From each participant, the hand with the most
severely affected finger joints was assigned to the inter-
vention group; the other hand served as a control. Pain on
VAS had significantly improved in the infliximab group
after 12 months compared with baseline [mean (SD) 32.5
(15.1) vs. 75.3 (10.2), respectively, on a 100-mm VAS] and
not in the placebo group [62.5 (20.4) vs. 50.5 (13.0)]. A
formal between-group comparison was not possible due to
the (known) baseline differences between the intervention
and placebo groups. Pain on pressure also improved only in
the infliximab group, although no differences between
groups were found for the other reported efficacy outcomes
(i.e. grip strength, morning stiffness and radiological
score). No side effects, either local or systemic, were
observed during the study.
One study (n = 60, unclear risk of bias) investigated
intra-articular dextrose injections compared with corticos-
teroid injections in participants with CMC OA [23]. Pain
during movement on VAS improved in both groups, with
better pain relief 24 weeks after the last injection in the
dextrose group compared with the corticosteroid group
[mean (SD) score on a 10-cm VAS after 24 weeks of 1.2
(1.6) vs. 2.4 (1.8), respectively]. The outcomes function
and joint pain on pressure also improved more in the
dextrose group than in the corticosteroid group [function
after 24 weeks: 1.6 (1.3) vs. 2.6 (1.5) on the Health
Assessment Questionnaire Disability Index (scale 0–9,
higher is worse); results for pain on pressure were only
presented graphically]. No between-group differences were
found for pinch strength. Three participants experienced
minor adverse events (increase in joint pain, which sub-
sided in several days), although which treatment these
participants had received is unclear.
Two studies compared different frequencies or different
forms of hyaluronic acid with each other in participants
with CMC OA. The first study (n = 42, high risk of bias)
compared a single injection of hyaluronic acid with either
2- or 3-weekly injections [28, 29]. Pain on VAS improved
only in both groups with multiple injections and not in the
group with a single injection, although no between-group
differences were found after 12 weeks [mean (SD) score on
a 100-mm VAS after 12 weeks of 43.1 (22.8) vs. 39.5
(28.6) vs. 29.8 (21.9), respectively, for one, two or three
injections]. Minor adverse events were observed in 30 % of
participants in all treatment groups, involving local pain,
swelling, heat and/or redness, which subsided within sev-
eral hours to days. The second study (n = 80, unclear risk
of bias) compared hyaluronic acid with a low molecular
weight with that with a high molecular weight [25]. Pain on
VAS improved in both treatment groups, although no
between-group differences were found after 12 weeks
[mean (SD) score on a 10-cm VAS after 12 weeks of 4.23
(2.90) vs. 4.03 (2.56), respectively, for the low versus high
molecular weight fluid]. Minor side effects were observed
in both groups, including mild pain and/or ecchymosis in
the injection site (exact numbers per treatment group not
specified).
4 Discussion
Based upon trials of variable quality, both intra-articular
corticosteroid injections and intra-articular hyaluronic acid
injections appear not to be more efficacious than placebo in
participants with CMC OA. A pooled analysis of two trials
(low and unclear risk of bias) comparing corticosteroid
with placebo injections in participants with CMC OA
demonstrated no between-group difference in pain up to
26 weeks. However, one trial with a low risk of bias
showed that intra-articular corticosteroid injections might
be more effective than placebo in relieving both pain
during joint movement and joint swelling in participants
with IP OA. This between-group difference also reached
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clinical significance with a minimal clinically important
difference (MCID) of 0.9 cm on a 10-cm VAS, based on
studies in participants with OA of the lower extremities, in
the absence of an MCID based on studies with patients
with hand OA [12]. This finding possibly suggests different
effects of intra-articular corticosteroid injections in differ-
ent subsets of hand OA, although this needs confirmation
since—to our knowledge—only one study to date has
investigated intra-articular corticosteroids in IP OA. It is
well known that CMC and IP OA are associated with a
separate risk factor profile, which underlines the different
nature of these two subsets of hand OA and thus the
possibility of different effects of the same intervention
[32]. It is possible that inflammation plays a bigger role in
IP OA than it does in CMC OA, in which mechanical
loading is known to be an important factor, explaining
why corticosteroids might be more effective in IP OA.
Several trials in this review, all with a high or unclear risk
of bias, compared corticosteroid versus hyaluronic acid
injections in participants with CMC OA, but no consistent
beneficial effect of one intervention over the other could
be demonstrated. Single studies, all judged to have a high
or unclear risk of bias, investigated alternative intra-ar-
ticular therapies, including infliximab versus placebo
(possible beneficial effect of infliximab, although no for-
mal comparison could be made), dextrose versus corti-
costeroid injections (more improvement of pain during
movement, pain on pressure and function in the dextrose
group), single versus two or three hyaluronic acid injec-
tions (no between-group differences) and low versus high
molecular weight hyaluronic acid (no between-group
differences).
Apart from local adverse events at the injection site,
including local pain, swelling and skin and/or nail abnor-
malities, no important adverse events were reported in any
of the trials, indicating that the intra-articular therapies
studied in this review appear to be relatively safe. Based on
the included studies, none of the intra-articular therapies
appeared to be more harmful than another. However,
studies were small and possibly underpowered to assess
adverse events. A large meta-analysis investigating the
benefits and harms of viscosupplementation for knee OA
found a clinically important increase in the risk for serious
adverse events, withdrawals because of adverse events, and
local adverse events associated with the use of intra-artic-
ular hyaluronic acid [12]. However, dosages of hyaluronic
acid used in studies in hand OA (range 5–15 mg per
injection) were generally significantly lower than the
dosage commonly used in the treatment of knee OA
(usually 20–40 mg per injection), possibly decreasing the
risk of adverse events. A network meta-analysis investi-
gating all pharmacological interventions in knee OA
reported more withdrawals due to adverse events in oral
treatments (i.e. acetaminophen and NSAIDs) than in intra-
articular therapies [33]. The most commonly reported
adverse events among intra-articular therapies for knee OA
were similar to those found in this review, i.e. transient
local reactions, with similar events reported in different
intra-articular therapies (corticosteroids and hyaluronic
acid). Since all included studies were of a short duration,
we cannot draw conclusions on long-term safety and/or
potential side effects associated with repeated intra-artic-
ular injections in the finger joints.
Studies systematically evaluating the benefits and harms
of intra-articular therapies in hand OA are scarce, although
many studies have been performed in knee OA, with
conflicting results [9, 12, 34–37]. A recently published
network meta-analysis comparing the effects of all avail-
able treatments in knee OA showed that intra-articular
therapies were the most effective form of treatment [33].
The authors of this meta-analysis also found that intra-
articular injection with placebo had an effect on pain
similar to that of an (oral) NSAID, both with an effect size
of 0.3. The intra-articular delivery mode itself thus appears
to have a large positive treatment effect, which could be a
true placebo response or possibly a physiological effect
after injecting a fluid into a joint with a needle. The posi-
tive treatment effect of intra-articular injections in general
was also confirmed by our finding that, in all placebo-
controlled studies, not only the intervention group, but also
the placebo group improved over time.
One of the strengths of our study was the use of a rig-
orous search strategy, minimizing the risk of missing eli-
gible studies. In an attempt to reduce the risk of publication
bias, we also searched for unpublished literature. This
yielded two additional potentially relevant trials for
inclusion, but both trials were eventually excluded, since
one trial (hyaluronic acid vs. corticosteroids in CMC OA)
was prematurely terminated due to adverse events in the
hyaluronic acid group (trial registration number
ISRCTN63038599), and results from the other (hyaluronic
acid vs. placebo in CMC OA) were unobtainable because
the pharmaceutical company funding the trial did not
pursue the indication (trial registration number
NCT00423371). Furthermore, through database searching
we retrieved a trial comparing a thumb splint alone versus a
single intra-articular corticosteroid injection in the CMC
joint in addition to a thumb splint, which did not fulfil our
inclusion criteria since it was only presented as an abstract
at a conference meeting more than 5 years ago [38]. In this
trial, no sustained benefit from a corticosteroid injection in
addition to wearing a thumb splint could be demonstrated.
Despite rigorous searching, no full trial report of this study
could be identified. The exclusion of the three above-
mentioned trials has possibly introduced a risk of publi-
cation bias. However, we believe it is unlikely that
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including these three studies would have led to major
implications for the conclusions of our review, since we
found no clear positive effect of any of the intra-articular
therapies studied.
An important limitation is the poor methodological
quality of many of the included trials, which is (partly)
reflected by the fact that many of the included studies were
judged as having an overall high risk of bias. Moreover,
many studies did not provide data eligible for meta-anal-
ysis (e.g. authors presented data only in figures or pre-
sented point estimates without a measure of variance). We
decided to only perform meta-analysis if the study data
were clinically and statistically sufficiently homogeneous
and/or the risk of bias was judged to be low enough to
produce reliable results. This decision was made based on
previous reports that different forms of bias can have a
major impact on the estimates of treatment benefits in
osteoarthritis trials [39–41]. Consequently, pooled analysis
was only possible in the comparison of corticosteroid
injections versus placebo in participants with CMC OA.
Although this comparison consisted of three trials, only
two of these were included in the meta-analysis, since the
third trial only presented data in figures and its trial pop-
ulation was also too different from that of the other two
studies (i.e. participants were only included when they had
previously experienced at least a mild to moderate
improvement after a corticosteroid injection in the CMC
joint). However, we believe that further studies with higher
methodological quality are not likely to substantially
change the conclusions of this review. Confounding from
biases across studies would have likely favoured the intra-
articular treatment, and correcting for these biases is thus
unlikely to change the direction of results towards a benefit
of intra-articular treatment with corticosteroids or hya-
luronic acid for hand OA compared with placebo. Our
decision not to include all available studies in a meta-
analysis likely explains why our findings differ slightly
from those of a recently published systematic review
evaluating the effectiveness of intra-articular corticos-
teroids and hyaluronic acid in participants with thumb-base
OA [13].
It is known that generalizing results from the specialized
and highly controlled setting of an RCT to real-life settings
can sometimes be troublesome, and it could be argued that
(the lack of) treatment effects found in the trials in our
review might not be consistent with experiences from
clinical practice. However, we believe that evidence from
RCTs, provided that such a study is well-executed, is the
most reliable form of evidence we have, since it accounts
for several important forms of bias. Reasons that clinicians
might see a treatment effect from any form of intra-artic-
ular therapy despite it not being found in the studies in this
review, are, for example, a ‘regression to the mean’ effect
because patients come to their treating physician when
complaints are at the maximum level, and the placebo
effect.
We aimed to include all possible intra-articular therapies
for hand OA in this review, and our extensive database
search also retrieved a few studies investigating prolother-
apy in hand OA. Prolotherapy is a form of treatment in
which repeated injections with an irritating substance are
given around the joint (peri-articular). A commonly used
substance for this purpose is dextrose, which is the com-
pound that is also studied by one of the included studies
[23]. However, since most studies investigating prolother-
apy did not clearly indicate whether the solution was only
injected peri-articularly or whether it entered the intra-ar-
ticular space, we excluded studies investigating prolother-
apy unless they clearly specified that the investigated
solution was injected intra-articularly. This led to the
exclusion of one RCT comparing dextrose prolotherapy
(n = 13) versus placebo (n = 14) in participants with fin-
ger and thumb OA, reporting that pain at rest and with grip
improved more in the dextrose group, although not signif-
icantly, and pain with movement as well as finger flexion
improved significantly more in the dextrose group [42].
5 Conclusions
For patients with CMC OA, intra-articular injections with
corticosteroids or hyaluronic acid do not seem to be more
effective than placebo, although in the short term these
treatments are probably not associated with important
adverse events other than local side effects. Despite the
apparent beneficial safety profile of intra-articular treat-
ments, at least in short-term use, which would suggest an
interesting treatment option for clinicians treating elderly
patients, the lack of efficacy discourages the use of these
treatments for hand OA. More well-performed studies
investigating these therapies in this patient group are
unlikely to substantially change this conclusion. Findings
from one well-performed study suggested that intra-artic-
ular corticosteroid injections might be effective compared
with placebo for patients with IP OA, although this finding
needs to be confirmed in future studies.
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